Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase IIa, Non-randomized Study of Alpharadin in Breast Cancer Patients With Bone Dominant Disease no Longer Considered Suitable for Endocrine Therapy

Next Previous
Trial Profile

An Open-label Phase IIa, Non-randomized Study of Alpharadin in Breast Cancer Patients With Bone Dominant Disease no Longer Considered Suitable for Endocrine Therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Advanced breast cancer; Bone metastases
  • Focus Pharmacodynamics
  • Sponsors Bayer HealthCare Pharmaceuticals

Most Recent Events

  • 09 Feb 2012 Primary endpoint 'N-telopeptide-of-the-cross-links-of-collagen' has been met.
  • 09 Feb 2012 Primary endpoint 'Alkaline-phosphatase-levels' has been met.
  • 09 Dec 2011 Results presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium and published in an Algeta media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top